99% Purity Factory Supply Roflumilast Pharmaceutical Roflumilast
Product Description
Product Details
| Product name |
Roflumilast |
| Cas number |
162401-32-3 |
| Apperance |
White to off-white powder |
| MF |
C17H14Cl2F2N2O3 |
| MW |
403.21 |
Roflumilast (CAS No. 162401-32-3) is a selective, long-acting phosphodiesterase-4 (PDE4) inhibitor used primarily for the treatment of chronic obstructive pulmonary disease (COPD). It exerts anti-inflammatory effects by increasing intracellular cyclic adenosine monophosphate (cAMP) levels, thereby reducing exacerbations in patients with severe COPD associated with chronic bronchitis.
Application&Function
Physical and chemical properties
White to light yellowish-brown solid granules or crystalline powder, odorless, slightly sweet in taste, and readily soluble in water.
Dosage and Administration
Roflurast is an oral tablet taken once daily. It should be used in combination with other bronchodilators. It is suitable for adult patients with a history of frequent exacerbations of chronic bronchitis and related severe COPD, and can be used for maintenance treatment. Its indications are: cough and excessive phlegm related to bronchitis in patients with severe COPD. The medication guidance information of roflurast approved by the U.S. Food and Drug Administration (FDA) indicates that it has potential mental health risks, including changes in mood, thinking or behavior, as well as unexplained weight loss. Roflurast is not expected to be used for the treatment of other symptoms of COPD, including emphysema. Roflurast cannot be used for the treatment of sudden respiratory problems (acute bronchospasm), nor is it recommended for patients under the age of 18. The main adverse reactions reported include: diarrhea, nausea, headache, insomnia, back pain, loss of appetite and dizziness.
Patent situation
The patent documents of roflurast compounds include IN2004MU00478, WO2005026095, WO2004033430, and US6822114. Roflurast has a compound patent in China titled "Fluoroalkoxy Substituted Benzamides and Their Preparation Methods and Applications" (WO09501338, CN94192659), which was applied for on July 2, 1994 and authorized on December 1, 1999. It protects the compound, the preparation method and its application in the treatment of airway diseases or skin diseases. The patent will expire on July 2nd, 2014.
Specification
ABOUT US
){kind=link}